Activated Protein Complex Concentrate in Emicizumab Prophylaxis

Here is a current open-access review describing APCC usage in emicizumab therapy: Sidonio RF Jr, Young G, Escuriola Ettingshausen C, et al. Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025;9:102926. doi: 10.1016/j.rpth.2025.102926. PMID: 40808796; PMCID: PMC12346059. Abstract Nonfactor therapies (NFTs) such as emicizumab are increasingly […]

Comments (0)

Bleeding Disorders

Oct 21 2025

george

University of Kansas Article About TTP

Here is an editorial review article about TTP that appears in the Spring-Summer edition of the University of Kansas “Kansas Medicine” magazine, entitled “In Their Blood.” The article features X. Long Zheng, MD, PhD, KU pathology head, who provided our January 6, 2021 webinar, “von Willebrand Factor, Friend or Foe?“

Bleeding Disorders

An Experimental Oral FVIII Mimetic

Click here in Hemostasis Today for a brief discussion of a developing phase 1 oral FVIII mimetic: Wolfgang Miesbach: Jan Astermark at the BIC 2025 presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A.

Bleeding Disorders

Incubation to Inactivate Efanesoctocog Alfa Prior to Inhibitor Bethesda Titer

Click here for an open-access letter that indicates the need to inactivate plasma EHL FVIII efanesoctocog alfa (Altuuviiio®; Altuvoct®) before performing a Bethesda titer to measure anti-FVIII inhibitor: Bowyer A. Is incubation for 30 minutes at 56°C sufficient to fully inactivate efanesoctocog alfa? Haemophilia. 2025. doi: 10.1111/hae.70137. PMID: 40985057. The findings provide a recommended incubation […]

Bleeding Disorders

WFH Fibrinogen Disorders Booklet

Click here for a recent WFH booklet, What Are Fibrinogen Disorders?

Bleeding Disorders

Effect of Rebalancing Therapy on Coagulation Assays

Click to read this open-access article that explores the effects of antithrombin reduction (rebalancing) hemophilia therapy on a series of coagulation tests: Chhabra, ES ; Liu, M. Evaluation of the interference of fitusiran and antithrombin lowering in plasma on routine coagulation assays. Research and practice in thrombosis and haemostasis, 2025;9:102989–9.

Bleeding Disorders

A Review of Current and Developing DOAC Reversal Agents

Check with your medical library for this comprehensive review of current and developing DOAC reversal agents: Gómez-Outes A, Suárez-Gea ML, Lecumberri R. When and how to use reversal agents for direct oral anticoagulants? Curr Cardiol Rep. 2023;25:371–80. doi: 10.1007/s11886-023-01858-x. PMID: 36976497. Abstract Purpose of review: Our objective is to describe currently available reversal agents for […]

Comments (0)

Anticoagulant Therapy

Sep 10 2025

george

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]

Bleeding Disorders

NXT007: A First-in-human Study of a Factor Bypassing Hemophilia Therapy

Check with your medical library for a copy of Sambe T, Miwa T, Yoneyama K, et al. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. J Thromb Haemost. 2025: S1538–7836(25)00399-X. doi: 10.1016/j.jtha.2025.06.013. PMID: 40554054. Here’s the abstract: Background: NXT007 is a bispecific antibody that mimics the cofactor function […]

Bleeding Disorders

Hemophilia After 2014

I (Geo) just added an updated ~40-minute audio PowerPoint module that describes hemophilia therapy after 2014, including extended half-life concentrates, factor bypassing therapy, genetic transfer of F8 and F9 genes, and rebalancing therapy. The module ends with a discussion of the laboratory means for monitoring the new therapeutics. Navigate to Educational Modules and click Hemophilia […]

Comments (0)

Bleeding Disorders

Bleeding Disorders

Activated Protein Complex Concentrate in Emicizumab Prophylaxis

University of Kansas Article About TTP

An Experimental Oral FVIII Mimetic

Incubation to Inactivate Efanesoctocog Alfa Prior to Inhibitor Bethesda Titer

WFH Fibrinogen Disorders Booklet

Effect of Rebalancing Therapy on Coagulation Assays

A Review of Current and Developing DOAC Reversal Agents

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

NXT007: A First-in-human Study of a Factor Bypassing Hemophilia Therapy

Hemophilia After 2014

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question